{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-003259","form_type":"8-K","ticker":"VOR","cik":"0001817229","company_name":"Vor Biopharma Inc.","filed_at":"2025-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.031317+00:00","generated_at":"2026-05-28T06:59:35.568861+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vor Bio appoints Erez Kalir to board, filling new seat linked to Reid Hoffman-led PIPE","bullets":["Board expanded from 7 to 8 members; Kalir designated by Reprogrammed Interchange (Hoffman entity).","Kalir is co-founder & COO of Manas AI, managing member of Martial Eagle Fund, venture partner at FJ Labs.","Standard director compensation: $40k cash retainer + option for 60k shares, plus annual 30k-share options.","Appointment follows a December 2024 PIPE led by Reid Hoffman; Kalir serves as Class III director until 2027.","Kalir's background includes Tiger Management, Sabretooth Capital, and a Rhodes Scholarship."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-003259","json":"https://secwatch.observer/filing/0001193125-25-003259.json","markdown":"https://secwatch.observer/filing/0001193125-25-003259.md","text":"https://secwatch.observer/filing/0001193125-25-003259.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817229/000119312525003259/0001193125-25-003259-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817229/000119312525003259/d861124d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T06:59:35.568861+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"691c6c8ed8","claim":"Erez Kalir was appointed as Director at Vor Biopharma Inc..","evidence_excerpt":"On January 6, 2025 the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”) increased the size of the Board from seven to eight members and appointed Erez Kalir to fill the resulting vacancy, to serve on the Board as an independent Class III director until the Company’s 2027 annual meeting of stockholders and until his successor is duly elected and qualified.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312525003259/0001193125-25-003259-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}